Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

DUPIXENT PROVIDED RAPID AND SUSTAINED
IMPROVEMENT IN NASAL CONGESTION AND
OBSTRUCTION

Significantly improved NC score at Weeks 24 (coprimary endpoint) and 52 (secondary endpoint) in patients who were uncontrolled on SOC1,2,a

Change in nc score through week 52 in trial 2
54%
Improvement

with DUPIXENT (baseline score 2.48) vs 16% improvement with placebo (baseline score 2.38) (LSM difference: -0.98 [95%: CI: -1.17, -0.79])

  • DUPIXENT 300 mg Q2W + INCS (n=150)
  • Placebo + INCS (n=153)
  • 51% improvement at Week 24 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) (-1.25 from a baseline score of 2.46) vs 16% improvement with placebo + INCS (n=153) (-0.38 from a baseline score of 2.38) (LSM difference: -0.87 [95% CI: -1.03, -0.71]) in Trial 21
    • NC score improved as early as Week 4 in Trial 2: -0.52 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) vs -0.16 with placebo + INCS (n=153) (LSM difference: -0.37 [95% CI: -0.46, -0.27])1,2
  • 59% improvement at Week 24 with DUPIXENT Q2W + INCS (-1.34 from a baseline score of 2.26) vs 18% improvement with placebo + INCS (-0.45 from a baseline score of 2.45) (LSM difference: -0.89 [95% CI: -1.07, -0.71]) in Trial 11
  • a All patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray.
  • Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.
  • INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks; SOC, standard of care.

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

References:

  1. DUPIXENT Prescribing Information.
  2. Data on file, Sanofi US. LIBERTY NP SINUS-52, CSR. 2018.